Cationic Solid-lipid nanoparticles as DNA carriers.

Combination treatment with celecoxib and DHMEQ or curcumin results in synergistic cell growth inhibition in hepatic cancer cells

Influence of MEK/ERK signaling on apoptosis induced by selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatocellular carcinoma cells

Influence of MEK/ERK signaling on apoptosis induced by selective COX-1 and COX-2 inhibitors in human hepatocellular carcinoma cells

Potentiation of antitumor effects of NSAIDs by inhibition of MEK/ERK activity in human hepatocellular carcinoma cells

Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors

The aim of the present study was to examine the effects of nonselective (indomethacin) and selective cyclooxygenase-2 (COX-2) inhibitors (NS-398, nimesulide, and CAY10404) on cell growth, cell cycle distribution, and apoptosis in three human hepatocellular carcinoma cell lines (HepG2, HuH-6, and HA22T/VGH) with different characteristics of differentiation and biological behavior. The four COX inhibitors showed a dose-dependent growth-inhibitory effect in all the cell lines. No substantial arrests in the progression of the cells through the cell cycle were observed after treatment of HuH-6 or HA22T/VGH for 48 h with the various inhibitors. On the other hand, there were significant increases …

Combination of the selective COX-2 inhibitor Celecoxib and the proteasome inibitor MG132 synergistically induces anti-proliferative and pro-apoptotic activity in liver cancer cells: possible involvement of endoplasmic reticulum stress response

Inhibition of the MEK/ERK pathway enhances apoptosis induced by selective COX-1 and COX-2 inhibitors in human hepatocellular carcinoma cells

Antitumor effects of the selective cycloxygenase-1 inhibitor SC-560 is potentiated by inhibition of MEK/ERK pathway in human hepatocellular cells.